<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>23522799</identifier>
<setSpec>1578-8989</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Méndez Machado, Gustavo Francisco</dc:author>
<dc:author>Angulo Guerrero, Jesús Ofelia</dc:author>
<dc:author>Campos Mondragón, Martha Gabriela</dc:author>
<dc:author>Martínez Martinez, Angélica</dc:author>
<dc:author>Oliart Ros, Rosa María</dc:author>
<dc:description xml:lang="en">BACKGROUND AND OBJECTIVE Metabolic syndrome (MS) frequency is growing and diet has an important influence on its evolution. Our objective was to study the effect of 3 sources of polyunsaturated fatty acids on MS parameters in humans. PATIENTS AND METHOD The MS was diagnosed according to the International Diabetes Federation. Three groups of individuals (n=15/group) were quasi-randomly assigned to one of the following treatments during 6 weeks: a) 1.8 g/d n-3 (1.08g eicosapentoaenoic acid+0.72 g docosahexaenoic acid); b) 2.0 g/d conjugated linoleic acid (CLA, 50:50, cis9:trans11, trans10:cis12), and c) 40 g/d walnut. The clinical and biochemical parameters were evaluated at the beginning and the end of the essay. RESULTS In the group with n-3 the triglycerides level decreased from 183.9 ± 35.2mg/dl to 149.6 ± 29.0mg/dl (P=.007). In the group with walnut the HDL level rose from 41.7 ± 5.2mg/dl to 47.8 ± 5.4 mg/dl (P=.004) and the Castelli index (total cholesterol/HDL) decreased from 4.86 ± 0.97 to 3.82 ± 0.81 (P=.004). There were not significant changes in the CLA group. At the end of the essay, 46.7% of walnut group patients, 46.7% of n-3 group and 20% of CLA group, had no MS. CONCLUSIONS The groups that consumed polyunsaturated fatty acids n-3 and those in walnut in moderate daily doses during 6 weeks had an improvement of the dyslipidemia component of MS, hypertriglyceridemia and low HDL level.</dc:description>
<dc:type>Journal Article</dc:type>
<dc:language>es</dc:language>
<dc:subject>Dieta</dc:subject>
<dc:subject>Diet</dc:subject>
<dc:subject>Dyslipidemia</dc:subject>
<dc:subject>Ácidos grasos</dc:subject>
<dc:subject>Dislipidemia</dc:subject>
<dc:subject>Fatty acids</dc:subject>
<dc:date>2013 Dec 21 </dc:date>
<dc:title xml:lang="es">Reversión del síndrome metabólico por el consumo de ácidos grasos poliinsaturados.</dc:title>
<dc:title xml:lang="en">[Metabolic syndrome reversion by polyunsaturated fatty acids ingestion].</dc:title>
<dc:publisher>Medicina clinica</dc:publisher>
</metadata>
</record>
</pubmed-document>
